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Abstract
Background—Metabolic syndrome (MetS) is an important etiologic and prognostic factor for 
cancer, but few studies have assessed hospitalization outcomes among patients with both 
conditions.
Methods—Data was obtained from the Healthcare Cost and Utilization project Nationwide 
Inpatient Sample (HCUP-NIS). Study variables were assessed using ICD-9 codes on adults aged 
40 years and over admitted to a US hospital between 2007 and 2011 with primary diagnosis of 
either breast, colorectal, or prostate cancer. We examined in-hospital mortality, post-surgical 
complications, and discharge disposition among cancer patients with MetS and compared with 
non-MetS patients.
Results—Hospitalized breast (OR: 0.31, 95% CI: 0.20–0.46), colorectal (OR: 0.41, 95% CI: 
0.35–0.49), and prostate (OR: 0.28, 95% CI: 0.16–0.49) cancer patients with MetS had 
significantly reduced odds of in-hospital mortality. The odds of post-surgical complications among 
breast (OR: 1.20, 95% CI: 1.03–1.39) and prostate (OR: 1.22, 95% CI: 1.09–1.37) cancer patients 
with MetS were higher, but lower by 7% among colorectal cancer patients with MetS. 
Additionally, breast (OR: 1.21, 95% CI: 1.11–1.32) and colorectal (OR: 1.06, 95% CI: 1.01–1.11) 
cancer patients with MetS had significantly higher odds for discharge to a skilled nursing facility 
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compared with those without MetS, but this was not statistically significant among prostate cancer 
patients.
Conclusions—Adverse health outcomes were significantly higher among hospitalized patients 
with a primary diagnosis of cancer and MetS. Future studies are needed to identify clinical 
strategies for detecting and managing patients with MetS to reduce the likelihood of poor inpatient 
outcomes.
Keywords
Metabolic syndrome; Cancer; In-hospital mortality; Inpatient outcomes
Introduction
Incidence rates for cancer and metabolic syndrome (MetS) have continued to increase 
dramatically in the USA and globally [34]. MetS is defined clinically as a cluster of 
interrelated biochemical conditions that include abdominal obesity, insulin resistance, 
dyslipidemia, and hypertension, and this condition has been associated with significantly 
increased risk for coronary heart disease, stroke, and type 2 diabetes [8, 24, 27, 33]. Recent 
epidemiologic evidence also suggests that MetS is an important etiologic factor for the 
development of cancer [47], as well as poor prognosis for common cancer types including 
breast and colorectal cancer [20]. The prevalence of both MetS and cancer increases 
dramatically with age [46], and with the rapid aging of the US population, adverse health 
outcomes for millions of adults, as well as healthcare costs, are likely to be significant [11].
Currently, at least a third of the general US adult population meet the current clinical criteria 
for MetS based on analysis of the National Health and Nutritional Survey (NHANES 2003–
2012), with prevalence increasing to about 50% among those ages 60 years and older [1]. 
Individual components such as obesity [15], diabetes [6, 37], and hypertension [19, 23] have 
long been shown to increase the risk of medical complications, overall and cancer-specific 
mortality. However, health outcomes among hospitalized patients, who are likely older, more 
vulnerable, and with more severe health-related conditions, have not been well evaluated. 
Prior studies have reported strong positive associations between MetS and incidence and 
mortality due to breast [12, 20], colorectal [5, 20], liver [20], and bladder cancers [20], but 
hospitalized patients, particularly those with the most common cancer types in US adults 
(breast, prostate, and colorectal cancer), need further study. Hence, the purpose of this study 
is to examine health outcomes, specifically in-hospital mortality, post-surgical 
complications, and discharge disposition, among hospitalized cancer patients with a clinical 
diagnosis of MetS.
Methods
Study Population
This cross-sectional study was conducted among breast, colorectal, and prostate cancer 
patients ages 40 years and older admitted to a US hospital between 2007 and 2011. Clinical 
data were obtained from the Healthcare Cost and Utilization Project (HCUP) Nationwide 
Inpatient Sample (NIS), which covers over 1000 hospitals in the USA and includes data on 
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over seven million hospital stays. Further details about NIS can be obtained from http://
www.hcupus.ahrq.gov/nisoverview.jsp.
Clinical and Individual Variables
International Classification of Disease, ninth edition ICD-9 codes for breast (ICD-9 codes: 
174.x), colorectal (ICD-9 codes: 153.x, 154.0–154.3, 154.8), and prostate cancer (ICD-9 
code: 185) recorded during admissions were assessed. Patients in whom the diagnosis of 
interest was not coded in first two diagnostic fields were excluded in order to exclude 
patients with underlying conditions. In addition, data on race, age, gender, area-level 
income, residential region, and insurance status were obtained from the NIS dataset. As 
cancer stage data is not captured in the dataset, a proxy cancer stage variable was created 
using the clinical criteria of disease staging, with patients categorized as metastatic when 
ICD-9 code indicated metastatic disease to other organs (196.x, 197.x, 198.x, 199.0–199.1) 
and non-metastatic when those codes were absent. Several studies have used similar staging 
criteria using the HCUP-NIS database [4]. Hospital length of stay was calculated by 
subtracting the number of days between admission and discharge, with same-day stays 
coded as 0. Surgical treatment for breast, colorectal, and prostate cancer was classified using 
diagnostic and procedure codes similar to those used in prior studies with HCUP NIS data 
(ICD-9 codes: breast: 85.41–85.48, 85.20–85.23; colorectal: 17.33–17.36, 17.39, 45.7×, 
45.80–45.82, 48.42–48.43, 48.49, 48.50–48.52, 48.63–48.65; prostate: 60.2–60.6) [2, 3, 32].
Study Exposure
Metabolic syndrome (MetS) was defined based on diagnosis codes (ICD-9 code: 277.7) or 
having at least three out of five components of MetS, namely, high blood pressure (ICD-9 
codes: 401–405), BMI ≥ 30 (ICD-9 codes: V85.3-V85.4, 278.01, 278.03), altered fasting 
glucose (ICD-9 codes: 250.00, 250.02, 250.10, 250.12, 250.20, 250.22, 250.30, 250.32, 
250.40, 250.42, 250.50, 250.52, 250.60, 250.62, 250.70, 250.72, 250.80, 250.82, 250.90, 
250.92), low HDL cholesterol (ICD-9 codes: 272.5–272.6), and high triglycerides (ICD-9 
codes: 272.1–272.4). This definition was chosen to approximate the definition published by 
the US National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) 
[7] previously examined in the NIS database [31] and Surveillance, Epidemiology, and End 
Results-Medicare database [42]. A modified Deyo comorbidity index [4] was created to 
account for the number of comorbid conditions present upon admission among patients, and 
those included myocardial infarction, chronic heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic 
ulcer disease, mild liver disease, hemiplegia, paraplegia, renal disease, liver disease, and 
HIV/AIDS.
Outcome Measures
The main study outcomes assessed for cancer patients were in-hospital mortality, post-
surgical complications, and discharge disposition. In-hospital mortality was defined as 
deaths occurring during hospitalization; post-surgical complication was defined using ICD-9 
codes associated with mechanical wounds, infection, renal, gastrointestinal, cardiovascular 
or pulmonary complications, as well as intra-operative complications. Discharge disposition 
is based on whether patients are discharged to recover at home or in other facilities such as 
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nursing homes, and was classified into the following: (1) routine discharge: discharged to 
home or self-care; (2) discharge to a skilled nursing facility; (3) expired/died; and (4) other
—classified as discharged due to any other reasons not stated above [10, 16].
Statistical Analysis
Descriptive statistics was conducted using Chi-square tests for categorical variables and t 
test for continuous variables, and the proportion of cancer in patients with MetS was 
assessed. Multivariable logistic regression analysis was used to determine the association 
between MetS and in-hospital mortality, complications, and discharge disposition separately 
for breast cancer in women only, prostate cancer in men only, and colorectal cancer in both 
men and women. All models were adjusted for age, race, stage, income, insurance and 
residential region, number of comorbidities, treatment, stage, and length of stay. 
Additionally, models for discharge disposition and in-hospital mortality were also adjusted 
for complications, and models for colorectal cancer were also adjusted for gender. All 
statistical analyses were performed with SAS 9.4 (Cary, NC).
Results
MetS was present in 5.2, 6.9, and 5.5% of hospitalized breast (70,916), colorectal (152,952), 
and prostate (87,623) cancer patients, respectively (Table 1). MetS was more prevalent in the 
older age groups of 60–69 years (7.3% in breast, 8.6% in colorectal, and 6.2% in prostate 
patients) compared with younger age groups (1.4% in breast, 2.6% in colorectal, and 2.9% 
in prostate cancer). For breast (8.% vs. 4.5%), colorectal (7.4% vs. 6.7%), and prostate 
(7.6% vs. 4.9%) cancer patients, MetS prevalence was higher among Blacks compared to 
Whites. In addition, patients residing in the lowest socioeconomic status (SES) regions had 
higher prevalence of MetS compared with those in the highest SES regions across all three 
cancer types. Regardless of cancer type, patients on Medicare had much higher MetS 
prevalence compared with those with private or other insurance types.
After adjusting for demographics, SES, insurance, and stage (Table 2), breast (OR: 0.31, 
95% CI: 0.20–0.46) and prostate (OR: 0.28, 95% CI: 0.16–0.49) cancer patients with MetS 
had a 70–80% lower odds of in-hospital deaths, while colorectal cancer patients experienced 
about 60% reduced odds (OR: 0.41, 95% CI: 0.35–0.49). However, increasing number of 
comorbidities was associated with about 43% increased odds of in-hospital mortality across 
the three cancer types (breast: OR: 1.43, 95% CI: 1.31–1.57; colorectal: OR: 1.46, 95% CI: 
1.41–1.51; prostate: OR: 1.44, 95% CI: 1.31–1.58), excluding comorbid conditions included 
in the definition of MetS. There was a 20–22% increased odds of post-surgical 
complications among breast (OR: 1.20, 95% CI: 1.03–1.39) and prostate (OR: 1.22, 95% CI: 
1.09–1.37) cancer patients with MetS, but a 7% decreased odds among colorectal cancer 
patients (OR: 0.93, 95% CI: 0.88–0.99) with MetS (Table 3). Increasing number of 
comorbid conditions also increased the odds of post-surgical complications among breast 
cancer patients (OR: 1.10, 95% CI: 1.03–1.17), but reduced the odds among colorectal 
cancer patients (OR: 0.90, 95% CI: 0.88–0.92). Breast (OR: 1.21, 95% CI: 1.11–1.32) and 
colorectal (OR: 1.06, 95% CI: 1.01–1.11) cancer patients with MetS were significantly more 
likely to be discharged to a skilled nursing facility compared with those without MetS (Table 
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4). Prostate cancer patients with MeS were also 10% more likely to be discharged to skilled 
nursing facilities; however, this was not statistically significant.
Discussion
In a large dataset of hospitalized cancer patients, we observed that 5 to 7% of breast, 
colorectal, and prostate cancer patients met the criteria for MetS using the NCEP ATP III 
definition [7]. The observed prevalence of MetS among hospitalized cancer patients 
increased with age and was much higher among Blacks and Hispanics compared with 
Whites, and higher among residents of lower SES regions compared with higher SES 
regions. These demographic patterns are similar to those observed in the general US 
population [1], and other studies have reported a prevalence of about 9% among patient 
populations in the HCUP NIS [31]. About a third of the general US adult population 
currently meets the criteria for MetS, with significantly increasing trends observed in the 
past few decades [41]. Differences in the availability of relevant data items in routine 
healthcare claim databases such as the HCUP likely contributed to our observed lower 
estimate. Nevertheless, significant increases in the prevalence of MetS are expected to 
continue due to demographic changes (due to the aging of the US population) and trends in 
lifestyle risk factors (such as obesity, physical activity, and diet). These risk factors also 
independently contribute to cancer risk and prognosis, making the assessment of the impact 
of metabolic syndrome on cancer outcomes highly relevant.
We observed that breast, colorectal, and prostate cancer patients with MetS had lower odds 
of in-hospital mortality, but higher odds of post-surgical complications and discharge to 
skilled nursing facilities. Other studies have reported a positive association between MetS 
and cancer mortality [17, 25, 43] with result showing increased risk of cancer-related 
mortality among individuals with MetS, and other studies have reported increased risk of 
post-surgical complications among patients with MetS [30]. Our finding of an inverse 
association between MetS and in-hospital mortality may be due to several factors: (1) 
differences in the specific MetS criteria used, (2) tumor-specific differences in the 
association between MetS and cancer mortality that may be masked by examining overall 
cancer mortality, and/or (3) differences in study population examined. In this study, we 
focused on hospitalized cancer patients, who are likely to be at more advanced stages of 
disease and hospitalized for surgery or treatment of other cancer-related complications. This 
study population is also unique in several ways. For instance, the severity of the cancer 
diagnosis and complicated treatment process may have led to mis-classification of MetS 
status if relevant data on diabetes, cholesterol, or BMI are not routinely captured/recorded in 
the medical records. In addition, an underlying MetS condition may be considered 
secondary to the primary cancer diagnosis during admission, and thus not addressed or 
evaluated during hospitalization. In addition, since MetS is associated with poorer 
hospitalization outcomes [9, 36, 38], this may have resulted in our observed higher odds of 
post-surgical complications and non-routine discharge, in which case mortality outcomes 
will occur outside of the hospital setting and thus will not be captured in the dataset.
There were increased odds of post-operative complications among breast and prostate cancer 
patients with MetS, but decreased odds for patients with colorectal cancer. This may be due 
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to differences in the types of surgical procedures. A major innovation in recent surgical 
techniques was the development of laparoscopic surgery for colon and prostate cancer [21, 
29, 45]. This less-invasive surgery type has been associated with significantly reduced rates 
of post-surgical complications, and a recent study observed that MetS was associated with 
poorer post-surgical outcomes following radical prostatectomy compared with those who 
received laparoscopic surgery [39]. We also observed significantly higher odds of breast and 
colorectal cancer patients with MetS to be discharged to skilled facilities. Our findings 
corroborate the existing literature showing that cancer patients with perioperative events, 
comorbidities, and surgical complications were at higher risk for rapid postoperative 
functional decline, leading to discharge to skilled facilities [16, 18, 44]. Taken together, 
these results suggest that the inverse association observed between MetS and in-hospital 
mortality is likely an artifact of the greater likelihood for these patients to experience post-
surgical complications and to be discharged to nursing facilities.
Given that millions of US adults currently meet the criteria for MetS, especially at older ages 
when the risk of chronic diseases like cancer is also highest, it is inevitable that a significant 
proportion of hospitalized patients will experience complications or adverse health outcomes 
more severe than indicated due to their current health condition. The question of whether 
health outcomes among cancer patients can be improved by controlling or eliminating MetS 
awaits large prospective studies. However, there is growing recognition of the importance of 
MetS as a significant public health issue, due to its independent association with worse 
health outcomes, as well as its role as an etiologic and/or prognostic risk factor for many 
other chronic diseases including cardiovascular diseases, stroke, chronic kidney diseases, 
and Alzheimer’s disease. MetS is also associated with increased healthcare utilization, 
longer hospital stay, increased healthcare costs, and need for post-hospitalization care. A 
critical need will be to identify which approaches should be taken to address or resolve 
components of MetS among pre-, peri-, or postoperative patients, who are at increased risk 
of complications. Hospitalized cancer patients with MetS may benefit from holistic clinical 
approaches to recognize components of MetS and its potential impact on health outcomes, 
and management strategies combining nutritional changes (e.g., low-carbohydrate dietary 
patterns shown to improve HDL, glucose, and HbA1C levels [13, 14, 22], prescribed 
physical activity (e.g., 30-min moderate physical activity 3–4 days/week to improve blood 
pressure and glycemic control [28, 40]), and/or the use of statins as lipid-lowering agents 
[35]. Future studies will be required to formally evaluate whether these combined 
behavioral/lifestyle approaches among cancer patients may improve post-operative outcomes 
and improve survival.
Several strengths and limitations are relevant to these study results. First, there is very little 
direct evidence regarding inpatient outcomes among adults with clinical diagnoses of MetS 
and cancer, despite the high prevalence of MetS in US adults, the common risk factors 
shared by both conditions, and the vulnerability of hospitalized patients. Second, use of the 
Nationwide Inpatient Survey provided objective clinical claims data on MetS and cancer 
diagnosis on a large sample of US adults, with baseline socio-demographic data that allowed 
us to adjust for potential confounders. As with most studies based on administrative claim 
database, the study was also subject to several limitations. First, our operational definition of 
MetS relied exclusively on ICD-9 codes documented in the NIS database and may be 
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vulnerable to misclassification and under-classification especially for MetS. The definition 
of MetS is ever-evolving [26] and included measurements of cholesterolemia, 
triglyceridemia, fasting plasma glycemia, and waist circumference. These may not always be 
assessed during admission for a primary diagnosis of cancer or may not be consistently 
recorded as diagnosis codes, potentially explaining the lower prevalence of MetS in our 
study sample. MetS was defined here based on the presence of diagnosis codes for at least 
three out of five components, following the definition proposed by the US National 
Cholesterol Education Program Adult Treatment Panel III [7] and similar to the 
methodology reported by other investigators [1, 31, 42]. Second, due to the cross-sectional 
nature of the dataset, we are unable to directly assess causality or account for individuals 
who have MetS components that are well controlled with medication. Nevertheless, we 
observed significantly worse health outcomes among patients with clinical diagnoses of 
MetS and cancer that warrant the early identification of these patients and formulation of 
clinical strategies to manage or eliminate components of MetS prior to surgery. Future 
studies are also needed to provide critical information regarding prevention and treatment 
strategies most appropriate for cancer patients, especially those who are sicker and 
hospitalized.
In conclusion, hospitalized patients with MetS and clinical diagnosis of breast, colorectal, 
and prostate cancer were less likely to experience in-hospital mortality, but were more likely 
to experience post-surgical complications and non-routine discharge to skilled nursing 
facilities. Clinical strategies for timely identification and control of MetS components may 
go a long way in reducing these adverse health outcomes among hospitalized patients.
Acknowledgments
Funding This study was funded by grant K01TW010271 from the National Institutes of Health. The content is 
solely the responsibility of the authors and does not necessarily represent the official views of the funding agency.
References
1. Aguilar M, Bhuket T, Torres S, et al. PRevalence of the metabolic syndrome in the united states, 
2003–2012. JAMA. 2015; 313(19):1973–4. DOI: 10.1001/jama.2015.4260 [PubMed: 25988468] 
2. Akinyemiju T, Sakhuja S, Vin-Raviv N. Racial and socio-economic disparities in breast cancer 
hospitalization outcomes by insurance status. Cancer Epidemiol. 2016a; 43:63–9. DOI: 10.1016/
j.canep.2016.06.011 [PubMed: 27394678] 
3. Akinyemiju T, Waterbor JW, Pisu M, et al. Availability of healthcare resources and colorectal cancer 
outcomes among non-Hispanic white and non-Hispanic black adults. J Community Health. 2016b; 
41(2):296–304. DOI: 10.1007/s10900-015-0096-z [PubMed: 26446012] 
4. Akinyemiju TF, Vin-Raviv N, Chavez-Yenter D, et al. Race/ethnicity and socio-economic 
differences in breast cancer surgery outcomes. Cancer Epidemiol. 2015; 39(5):745–51. DOI: 
10.1016/j.canep.2015.07.010 [PubMed: 26231096] 
5. Aleksandrova K, Boeing H, Jenab M, et al. Metabolic syndrome and risks of colon and rectal 
cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res 
(Phila). 2011; 4(11):1873–83. DOI: 10.1158/1940-6207.capr-11-0218 [PubMed: 21697276] 
6. Anand N, Chong CA, Chong RY, et al. Impact of diabetes on postoperative outcomes following 
colon cancer surgery. J Gen Intern Med. 2010; 25(8):809–13. DOI: 10.1007/s11606-010-1336-7 
[PubMed: 20352362] 
Akinyemiju et al. Page 7
Obes Surg. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
7. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, 
evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. 
Circulation. 2002; 106(25):3143. [PubMed: 12485966] 
8. Athyros VG, Ganotakis ES, Elisaf MS, et al. Prevalence of vascular disease in metabolic syndrome 
using three proposed definitions. Int J Cardiol. 2007; 117(2):204–10. DOI: 10.1016/j.ijcard.
2006.04.078 [PubMed: 16854482] 
9. Bai YM, Li CT, Tsai SJ, Tu PC, Chen MH, Su TP. Metabolic syndrome and adverse clinical 
outcomes in patients with bipolar disorder. BMC Psychiatry. 2016; 16(1):448. [PubMed: 27978821] 
10. Balentine CJ, Naik AD, Robinson CN, et al. Association of high-volume hospitals with greater 
likelihood of discharge to home following colorectal surgery. JAMA surgery. 2014; 149(3):244–
51. DOI: 10.1001/jamasurg.2013.3838 [PubMed: 24430092] 
11. Berger NA, Savvides P, Koroukian SM, et al. Cancer in the elderly. Trans Am Clin Climatol Assoc. 
2006; 117:147–56. [PubMed: 18528470] 
12. Bhandari R, Kelley GA, Hartley TA, et al. Metabolic syndrome is associated with increased breast 
cancer risk: a systematic review with meta-analysis. Int J Breast Cancer. 2014; 2014:189384.doi: 
10.1155/2014/189384 [PubMed: 25653879] 
13. Boden G, Sargrad K, Homko C, et al. Effect of a low-carbohydrate diet on appetite, blood glucose 
levels, and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med. 2005; 142(6):
403–11. [PubMed: 15767618] 
14. Brehm BJ, Seeley RJ, Daniels SR, et al. A randomized trial comparing a very low carbohydrate 
diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy 
women. J Clin Endocrinol Metab. 2003; 88(4):1617–23. DOI: 10.1210/jc.2002-021480 [PubMed: 
12679447] 
15. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer 
in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348(17):1625–38. DOI: 
10.1056/NEJMoa021423 [PubMed: 12711737] 
16. Cholankeril G, Hu M, Tanner E, et al. Skilled nursing facility placement in hospitalized elderly 
patients with colon cancer. Eur J Surg Oncol. 2016; 42(11):1660–6. DOI: 10.1016/j.ejso.
2016.06.005 [PubMed: 27387271] 
17. Colangelo LA, Gapstur SM, Gann PH, et al. Colorectal cancer mortality and factors related to the 
insulin resistance syndrome. Cancer Epidemiol Biomark Prev. 2002; 11(4):385–91.
18. Cramer JD, Patel UA, Samant S, et al. Discharge destination after head and neck surgery: 
predictors of discharge to Postacute care. Otolaryngol Head Neck Surg. 2016; 155(6):997–1004. 
DOI: 10.1177/0194599816661514 [PubMed: 27484235] 
19. Dyer AR, Stamler J, Berkson DM, et al. High blood-pressure: a risk factor for cancer mortality? 
Lancet (London, England). 1975; 1(7915):1051–6.
20. Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: a systematic review 
and meta-analysis. Diabetes Care. 2012; 35(11):2402–11. DOI: 10.2337/dc12-0336 [PubMed: 
23093685] 
21. Finkelstein J, Eckersberger E, Sadri H, et al. Open versus laparoscopic versus robot-assisted 
laparoscopic prostatectomy: the European and US experience. Rev Urol. 2010; 12(1):35–43. 
[PubMed: 20428292] 
22. Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N 
Engl J Med. 2003; 348(21):2082–90. DOI: 10.1056/NEJMoa022207 [PubMed: 12761365] 
23. Grossman E, Messerli FH, Boyko V, et al. Is there an association between hypertension and cancer 
mortality? Am J Med. 2002; 112(6):479–86. [PubMed: 11959059] 
24. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008; 28(4):629–36. 
DOI: 10.1161/atvbaha.107.151092 [PubMed: 18174459] 
25. Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin 
Nutr. 2007; 86(3):s843–57. [PubMed: 18265478] 
26. Johnson LW, Weinstock RS. The metabolic syndrome: concepts and controversy. Mayo Clin Proc. 
2006; 81(12):1615–20. DOI: 10.4065/81.12.1615 [PubMed: 17165640] 
27. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic 
stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic 
Akinyemiju et al. Page 8
Obes Surg. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cardiovascular disease. Stroke. 2005; 36(7):1366–71. DOI: 10.1161/01.str.0000169945.75911.33 
[PubMed: 15933253] 
28. Lakka TA, Laaksonen DE. Physical activity in prevention and treatment of the metabolic 
syndrome. Appl Physiol Nutr Metab Physiologie appliquee, nutrition et metabolisme. 2007; 32(1):
76–88. DOI: 10.1139/h06-113
29. Lepor H. Open Versus Laparoscopic Radical Prostatectomy. Rev Urol. 2005; 7(3):115–27. 
[PubMed: 16985822] 
30. Lohsiriwat V, Pongsanguansuk W, Lertakyamanee N, et al. Impact of metabolic syndrome on the 
short-term outcomes of colorectal cancer surgery. Dis Colon Rectum. 2010; 53(2):186–91. DOI: 
10.1007/DCR.0b013e3181bdbc32 [PubMed: 20087094] 
31. Memtsoudis SG, Kirksey M, Ma Y, et al. Metabolic syndrome and lumbar spine fusion surgery: 
epidemiology and perioperative outcomes. Spine. 2012; 37(11):989–95. DOI: 10.1097/BRS.
0b013e31823a3a13 [PubMed: 22024892] 
32. Milenkovic M, Russo CA, Elixhauser A. healthcare cost and utilization project (HCUP) statistical 
briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006. Hospital stays for 
prostate cancer, 2004: statistical brief #30. 
33. Nilsson PM, Engstrom G, Hedblad B. The metabolic syndrome and incidence of cardiovascular 
disease in non-diabetic subjects–a population-based study comparing three different definitions. 
Diabet Med. 2007; 24(5):464–72. DOI: 10.1111/j.1464-5491.2007.02142.x [PubMed: 17381496] 
34. O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its 
associated pathologies. Obes Rev. 2015; 16(1):1–12. DOI: 10.1111/obr.12229
35. Ott C, Schmieder RE. The role of statins in the treatment of the metabolic syndrome. Curr 
Hypertens Rep. 2009; 11(2):143–9. [PubMed: 19278604] 
36. Ounhasuttiyanon A, Lohsiriwat V. Metabolic syndrome and outcome after breast reconstruction. 
Gland Surg. 2014; 3(1):85–7. DOI: 10.3978/j.issn.2227-684X.2014.02.07 [PubMed: 25083501] 
37. Ranc K, Jorgensen ME, Friis S, et al. Mortality after cancer among patients with diabetes mellitus: 
effect of diabetes duration and treatment. Diabetologia. 2014; 57(5):927–34. DOI: 10.1007/
s00125-014-3186-z [PubMed: 24633676] 
38. Shehab A, Al-Dabbagh B, Almahmeed W, et al. Prevalence, characteristics, and in-hospital 
outcomes of metabolic syndrome among patients with acute coronary syndrome in the United 
Arab Emirates. Open Cardiovasc Med J. 2012; 6:81–7. DOI: 10.2174/1874192401206010081 
[PubMed: 22888374] 
39. Shiota M, Takeuchi A, Sugimoto M. , et al. The differential impact of body mass index and the 
feature of metabolic syndrome on oncological outcomes following different surgical procedures in 
Japanese men with prostate cancer. Ann Surg Oncol. 2016. 
40. Sigal RJ, Kenny GP, Wasserman DH, et al. Physical activity/exercise and type 2 diabetes. Diabetes 
Care. 2004; 27(10):2518–39. [PubMed: 15451933] 
41. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent 
predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010; 
59(10):1410–5. DOI: 10.1136/gut.2010.213553 [PubMed: 20660697] 
42. Trabert B, Wentzensen N, Felix AS, et al. Metabolic syndrome and risk of endometrial cancer in 
the united states: a study in the SEER-medicare linked database. Cancer Epidemiol Biomark Prev. 
2015; 24(1):261–7. DOI: 10.1158/1055-9965.epi-14-0923
43. Trevisan M, Liu J, Muti P, et al. Markers of insulin resistance and colorectal cancer mortality. 
Cancer Epidemiol Biomark Prev. 2001; 10(9):937–41.
44. Trinh QD, Bianchi M, Sun M, et al. Discharge patterns after radical prostatectomy in the United 
States of America. Urol Oncol. 2013; 31(7):1022–32. DOI: 10.1016/j.urolonc.2011.10.007 
[PubMed: 22100070] 
45. Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgery versus open surgery for colon cancer: 
short-term outcomes of a randomised trial. Lancet Oncol. 2005; 6(7):477–84. DOI: 10.1016/
s1470-2045(05)70221-7 [PubMed: 15992696] 
46. Veronica G, Esther RRM. Aging, metabolic syndrome and the heart. Aging Dis. 2012; 3(3):269–
79. [PubMed: 22724085] 
Akinyemiju et al. Page 9
Obes Surg. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
47. Zhou JR, Blackburn GL, Walker WA. Symposium introduction: metabolic syndrome and the onset 
of cancer. Am J Clin Nutr. 2007; 86(3):s817–9. [PubMed: 18265474] 
Akinyemiju et al. Page 10
Obes Surg. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Akinyemiju et al. Page 11
Table 1
Prevalence of metabolic syndrome (MetS) among patients with cancer; Nationwide Inpatient Sample 2007–
2011
Metabolic syndrome present N (%)
Breast cancer Colorectal cancer Prostate cancer
N 70,916 152,952 87,623
Overall with MetS 3702 (5.22) 10,543 (6.89) 4777 (5.45)
Age (years)
 40–49 210 (1.43) 360 (2.62) 108 (2.87)
 50–59 730 (1.03) 1612 (5.33) 1048 (4.39)
 60–69 1278 (7.34) 3215 (8.57) 2339 (6.25)
 70 and above 1484 (7.26) 5356 (7.50) 1282 (5.68)
Gender
 Females - 5148 (6.79) -
 Males - 5395 (6.99) -
Race
 Whites 2307 (4.51) 7558 (6.71) 3254 (4.91)
 Blacks 798 (8.63) 1434 (7.36) 874 (7.58)
 Hispanics 361 (6.19) 887 (7.79) 376 (6.90)
 Others 236 (5.36) 664 (7.02) 273 (6.22)
Region
 Large metropolitan 2218 (5.26) 5688 (6.79) 2655 (5.46)
 Small metropolitan 876 (4.95) 2803 (7.05) 1283 (5.20)
 Micropolitan 355 (5.44) 1161 (6.94) 505 (5.84)
 Non-metro non-micropolitan 253 (5.58) 891 (7.06) 334 (5.88)
Area-level income
 Q4-highest 831 (4.09) 2249 (6.38) 1264 (4.73)
 Q3 875 (5.16) 2601 (7.19) 1267 (5.69)
 Q2 919 (5.58) 2710 (6.94) 1166 (5.77)
 Q1-lowest 1077 (6.28) 2983 (7.01) 1080 (5.85)
Insurance
 Medicare 2133 (7.56) 6901 (8.01) 2294 (6.39)
 Medicaid 349 (4.86) 493 (4.49) 109 (4.99)
 Private 1101 (3.42) 2753 (5.98) 2192 (4.79)
 Other 119 (3.54) 396 (4.05) 182 (4.83)
Discharge disposition
 Routine discharge 1764 (4.40) 5223 (6.77) 3213 (5.15)
 Skilled nursing facility 966 (6.78) 3048 (7.40) 458 (6.31)
 Expired 19 (1.68) 123 (2.83) 10 (1.43)
 Other 953 (6.16) 2149 (7.10) 1096 (6.32)
Metastasis
 Non-metastatic 2665 (5.43) 7398 (7.79) 4447 (5.54)
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Metabolic syndrome present N (%)
Breast cancer Colorectal cancer Prostate cancer
 Metastatic 1037 (4.75) 3145 (5.43) 330 (4.60)
Cancer surgery*
 No 1930 (5.06) 4444 (6.28) 4777 (5.45)
 Yes 1772 (5.40) 6099 (7.82) -
Complications
 No 3490 (5.17) 8474 (6.96) 4404 (5.37)
 Yes 212 (6.31) 2069 (6.65) 373 (6.71)
No. of comorbiditiesa 0.49 (0.73) 0.59 (0.81) 0.34 (0.62)
Length of stay 2.80 (3.06) 7.11 (6.47) 2.62 (2.48)
a
Mean and standard deviation reported
bComorbidities assessed based on ICD9 codes for the following: myocardial infarction, chronic heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, hemiplegia, paraplegia, 
renal disease, liver disease, and HIV/AIDS
Row percent
Frequencies do not add up due to missing data
Obes Surg. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Akinyemiju et al. Page 13
Table 2
Association between metabolic syndrome (MetS) diagnosis and in-hospital mortality among patients with 
cancer, Nationwide Inpatient Sample, 2007–2011
Cancer type
Breast cancer AOR (95%CI) Colorectal cancer AOR (95%CI) Prostate cancer AOR (95%CI)
MetS diagnosis
 No Ref Ref Ref
 Yes 0.31(0.20–0.46) 0.41(0.35–0.49) 0.28(0.16–0.49)
Age groups
 ≧ 40 < 50 Ref Ref Ref
 ≧ 50 < 60 1.17(0.98–1.39) 1.17(1.01–1.34) 2.41(0.87–6.63)
 ≧ 60 < 70 1.58(1.31–1.89) 1.63(1.42–1.87) 4.56(1.68–12.36)
 ≧ 70 2.86(2.32–3.52) 3.40(2.96–3.90) 24.66(9.12–66.69)
Gender
 Males - Ref -
 Females - 0.86(0.82–0.92) -
Race
 Whites Ref Ref Ref
 Blacks 1.11(0.95–1.31) 1.08(0.99–1.18) 1.04(0.85–1.28)
 Hispanics 0.98(0.78–1.21) 0.91(0.82–1.03) 0.98(0.74–1.31)
 Others 0.90(0.69–1.18) 1.09(0.98–1.23) 0.83(0.59–1.17)
Region
 Large metro Ref Ref Ref
 Small metro 1.20(1.04–1.38) 1.03(0.96–1.10) 1.02(0.85–1.22)
 Micropolitan 1.48(1.21–1.82) 1.15(1.05–1.27) 1.19(0.93–1.54)
 Not metro or micro 2.06(1.66–2.54) 1.25(1.12–1.39) 2.40(1.88–3.08)
Area-level income
 Q4-highest Ref Ref Ref
 Q3 1.35(1.14–1.60) 0.98(0.90–1.07) 1.09(0.88–1.35)
 Q2 1.15(0.96–1.38) 1.02(0.93–1.11) 1.01(0.81–1.26)
 Q1-lowest 1.28(1.07–1.54) 0.98(0.90–1.07) 1.05(0.84–1.32)
Insurance
 Private Ref Ref Ref
 Medicaid 0.84(0.70–1.02) 0.91(0.80–1.03) 1.02(0.70–1.50)
 Medicare 0.41(0.35–0.49) 0.66(0.61–0.72) 0.36(0.30–0.43)
 Other 2.05(1.70–2.47) 1.73(1.55–1.92) 2.40(1.88–3.08)
# Comorbiditiesa 1.43(1.31–1.57) 1.46(1.41–1.51) 1.44(1.31–1.58)
Metastasis
 Non-metastatic Ref Ref Ref
 Metastatic 9.57(8.32–11.01) 2.43(2.30–2.58) 11.51(9.82–13.49)
Cancer surgery*
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Cancer type
Breast cancer AOR (95%CI) Colorectal cancer AOR (95%CI) Prostate cancer AOR (95%CI)
 No Ref Ref -
 Yes 0.02(0.01–0.03) 0.43(0.40–0.45) -
Length of Stay 1.05(1.05–1.06) 1.04(1.03–1.04) 1.04(1.03–1.05)
aComorbidities assessed based on ICD9 codes for the folowing: myocardial infarction, chronic heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, hemiplegia, paraplegia, 
renal disease, liver disease, and HIV/AIDS
*Cancer specific surgeries
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Table 3
Association between metabolic syndrome (MetS) diagnosis and complications among patients with cancer, 
Nationwide Inpatient Sample, 2007–2011
Cancer type
Breast cancer AOR (95%CI) Colorectal cancer AOR (95%CI) Prostate cancer AOR (95%CI)
MetS diagnosis
 No Ref Ref Ref
 Yes 1.20(1.03–1.39) 0.93(0.88–0.99) 1.22(1.09–1.37)
Age groups
 ≧ 40 < 50 Ref Ref Ref
 ≧ 50 < 60 1.07(0.97–1.19) 1.01(0.95–1.07) 1.10(0.94–1.28)
 ≧ 60 < 70 0.97(0.87–1.09) 1.03(0.97–1.09) 1.13(0.97–1.31)
 ≧ 70 0.92(0.80–1.06) 0.99(0.93–1.05) 0.77(0.65–0.91)
Gender
 Males - Ref -
 Females - 0.75(0.73–0.77) -
Race
 Whites Ref Ref Ref
 Blacks 0.94(0.84–1.06) 0.86(0.82–0.90) 1.05(0.96–1.14)
 Hispanics 0.93(0.81–1.07) 0.89(0.84–0.94) 1.01(0.89–1.14)
 Others 0.88(0.75–1.03) 0.94(0.89–1.00) 1.06(0.94–1.21)
Region
 Large metro Ref Ref Ref
 Small metro 1.05(0.97–1.15) 1.04(1.00–1.07) 1.14(1.06–1.22)
 Micropolitan 1.11(0.97–1.27) 1.12(1.07–1.18) 1.17(1.05–1.30)
 Not metro or micro 1.09(0.93–1.28) 1.03(0.97–1.08) 1.11(0.98–1.26)
Area-level income
 Q4-highest Ref Ref Ref
 Q3 1.00(0.91–1.10) 1.03(0.99–1.07) 0.98(0.90–1.06)
 Q2 1.00(0.90–1.11) 0.99(0.95–1.03) 1.03(0.95–1.12)
 Q1-lowest 0.92(0.82–1.03) 0.90(0.86–0.94) 0.96(0.88–1.06)
Insurance
 Private Ref Ref Ref
 Medicaid 0.89(0.78–1.01) 0.76(0.71–0.81) 0.73(0.61–0.89)
 Medicare 0.98(0.88–1.09) 0.97(0.93–1.01) 0.98(0.91–1.06)
 Other 0.89(0.78–1.01) 0.79(0.74–0.84) 0.91(0.79–1.05)
# Comorbiditiesa 1.10(1.03–1.17) 0.90(0.88–0.92) 0.96(0.90–1.01)
Metastasis
 Non-metastatic/in situ Ref Ref Ref
 Metastatic 0.68(0.63–0.74) 0.87(0.84–0.89) 0.30(0.24–0.56)
Cancer surgery*
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Cancer type
Breast cancer AOR (95%CI) Colorectal cancer AOR (95%CI) Prostate cancer AOR (95%CI)
 No Ref Ref -
 Yes 0.83(0.77–0.90) 2.28(2.22–2.35) -
Discharge disposition
 Routine discharge Ref Ref Ref
 Skilled nursing facility 1.34(1.23–1.47) 1.45(1.41–1.50) 1.03(0.93–1.14)
 Expired 0.57(0.40–0.80) 1.30(1.19–1.41) 0.37(0.24–0.56)
 Other 1.07(0.97–1.17) 1.41(1.36–1.46) 1.09(1.01–1.18)
Length of stay 1.08(1.07–1.09) 1.11(1.11–1.11) 1.26(1.25–1.27)
aComorbidities assessed based on ICD9 codes for the following: myocardial infarction, chronic heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, hemiplegia, paraplegia, 
renal disease, liver disease, and HIV/AIDS
*Cancer-specific surgeries
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Table 4
Association between metabolic syndrome (MetS) diagnosis and hospital discharge to a skilled nursing facility 
as compared to regular discharge of patients with cancer, Nationwide Inpatient Sample, 2007–2011
Cancer type
Breast cancer AOR (95%CI) Colorectal cancer AOR (95%CI) Prostate cancer AOR (95%CI)
MetS diagnosis
 No Ref Ref Ref
 Yes 1.21(1.11–1.32) 1.06(1.01–1.11) 1.10(0.98–1.23)
Age groups
 ≧ 40 < 50 Ref Ref Ref
 ≧ 50 < 60 1.15(1.08–1.23) 1.12(1.05–1.19) 1.03(0.86–1.22)
 ≧ 60 < 70 1.32(1.23–1.42) 1.20(1.13–1.27) 1.12(0.94–1.33)
 ≧ 70 2.38(2.20–2.58) 2.51(2.36–2.68) 2.60(2.17–3.11)
Gender
 Males - Ref -
 Females - 1.23(1.20–1.27) -
Race
 Whites Ref Ref Ref
 Blacks 1.05(0.98–1.12) 0.81(0.77–0.84) 1.27(1.18–1.38)
 Hispanics 0.98(0.90–1.07) 0.71(0.67–0.75) 0.81(0.72–0.92)
 Others 0.80(0.73–0.89) 0.76(0.71–0.81) 0.79(0.68–0.91)
Region
 Large metro Ref Ref Ref
 Small metro 0.71(0.67–0.75) 0.87(0.84–0.90) 0.78(0.73–0.83)
 Micropolitan 0.71(0.66–0.77) 0.92(0.88–0.96) 0.69(0.62–0.76)
 Not metro or micro 0.57(0.52–0.62) 0.83(0.79–0.87) 0.78(0.70–0.86)
Area-level income
 Q4-highest Ref Ref Ref
 Q3 0.93(0.88–0.99) 1.01(0.97–1.05) 1.09(1.01–1.18)
 Q2 1.02(0.96–1.09) 0.98(0.94–1.02) 1.19(1.09–1.29)
 Q1-lowest 0.95(0.89–1.02) 1.02(0.97–1.07) 1.13(1.03–1.23)
Insurance
 Private Ref Ref Ref
 Medicaid 1.01(0.93–1.10) 1.08(1.02–1.15) 1.81(1.54–2.12)
 Medicare 1.67(1.57–1.78) 1.51(1.44–1.57) 1.54(1.43–1.66)
 Other 0.55(0.49–0.63) 0.53(0.50–0.57) 0.71(0.60–0.83)
# Comorbiditiesa 1.22(1.17–1.27) 1.25(1.23–1.28) 1.35(1.29–1.41)
Metastasis
 Non-metastatic/in situ Ref Ref Ref
 Metastatic 1.43(1.37–1.50) 1.13(1.10–1.16) 2.02(1.86–2.19)
Cancer surgery*
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Cancer type
Breast cancer AOR (95%CI) Colorectal cancer AOR (95%CI) Prostate cancer AOR (95%CI)
 No Ref Ref -
 Yes 1.52(1.46–1.59) 0.56(0.54–0.57) -
Complications
 No Ref Ref Ref
 Yes 1.16(1.05–1.27) 1.28(1.24–1.33) 0.96(0.87–1.07)
Length of stay 1.16(1.15–1.17) 1.17(1.17–1.18) 1.26(1.25–1.27)
aComorbidities assessed based on ICD9 codes for the following: myocardial infarction, chronic heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, cardio-pulmonary disease, rheumatic disease, peptic ulcer disease, mild liver disease, hemiplegia, paraplegia, 
renal disease, liver disease, and HIV/AIDS
*Cancer-specific surgeries
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